NINA.CAPITAL

In our investment criteria and process, we are informed by a Stanford-born methodology of health technology innovation known as Biodesign. Since 2001, Biodesign has proven to de-risk the process of new venture creation by applying a need-driven and value-based approach to reinventing healthcare with the help of technology. (To learn more about the methodology, head to The Student Guide to Biodesign, developed by a team of Stanford instructors and students who are passionate about education and making high-quality learning materials available and accessible to all.)

 

We see our sweet spot at seeding founders who are marrying in-depth understanding of the complex network of healthcare system participants with meaningful engineering innovation, advanced data science, and information technology-enabled products and services. From our home base in Europe, we look for and support need-driven founders determined to effectively and efficiently serve these participants internationally.

 

We invest broadly across Europe, including the United Kingdom, in the United States, Canada, Israel, and Australia, with a collaborative approach in how we work and interact with other players in our industry. Our goal is to help thoughtful and committed teams bridge the chasm from founding to series A capital and access global markets.